Evidence map›Paper›PMID 31077558›Full record

ArticleCytometry. Part B, Clinical cytometry2019

Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.

Dalia A Salem, Drake Scott, Catharine S McCoy, David J Liewehr, David J Venzon, Evgeny Arons, Robert J Kreitman, Maryalice Stetler-Stevenson, Constance M Yuan

Open access · bronzeAbstract read
In one paragraph

Article in Cytometry. Part B, Clinical cytometry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Biology and Treatment of Hairy Cell Leukemia.Current treatment options in oncology · 2020
    Review
  13. Increased expression ofExperimental and therapeutic medicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Dalia A SalemLaboratory of Pathology, CCR, NCI, NIH, Bethesda, Maryland.
Drake ScottLaboratory of Pathology, CCR, NCI, NIH, Bethesda, Maryland.
Catharine S McCoyLaboratory of Pathology, CCR, NCI, NIH, Bethesda, Maryland.
David J LiewehrBiostatistics and Data Management Section, CCR, NCI, NIH, Bethesda, Maryland.
David J VenzonBiostatistics and Data Management Section, CCR, NCI, NIH, Bethesda, Maryland.
Evgeny AronsLaboratory of Molecular Biology, Clinical Immunotherapy Section, CCR, NCI, NIH, Bethesda, Maryland.
Robert J KreitmanLaboratory of Molecular Biology, Clinical Immunotherapy Section, CCR, NCI, NIH, Bethesda, Maryland.
Maryalice Stetler-StevensonLaboratory of Pathology, CCR, NCI, NIH, Bethesda, Maryland.
Constance M YuanLaboratory of Pathology, CCR, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-2601-3665
National Institutes of Health · USCenter for Cancer Research · USData Management (Italy) · IT

Funding

Flow Cytometric Evaluation of BiomarkersZICBC011104 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, HAO-WEI · 2009 to 2025
$8.6M
RECOMBINANT TOXINS FOR TREATMENT OF PATIENTS WITH HEMATOLOGIC MALIGNANCIESZ01BC010301 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KREITMAN, ROBERT · 1998 to 2008
$1.5M
Intramural NIH HHS Z01 BC010301Intramural NIH HHS ZIC BC011104
6 · The paper itself

Abstract

backgroundHairy cell leukemia (HCL) and hairy cell leukemia variant (HCLv) are rare diseases with overlapping clinicopathological features. Features distinguishing HCL from HCLv include expression of CD25, CD123, CD200, annexin-A1, and the presence of BRAF V600E mutation. HCLv typically lacks these markers, but they may occur in a subgroup of HCL patients with an aggressive clinical course. We examined CD43, CD81, CD79b, and CD200 expression in HCL and HCLv.

methodsMultiparametric flow cytometry (FCM) was performed on blood from 59 HCL and 15 HCLv patients for protocol entry. Mean fluorescent intensity (MFI) of CD43, CD79b, CD81, and CD200 was determined (for CD200, n = 17 and 7, respectively).

resultsMedian MFI of HCL vs HCLv was 545 vs 272 for CD43, 602 vs 2,450 for CD81, 4,962 vs 1,969 for CD79b, and 11,652 vs 1,405 for CD200, respectively. Analysis of the median differences, HCL minus HCLv (and their 95% confidence intervals and P-values) indicated that CD43 MFI (estimated median difference (95% CI): 212 [72-413; P = 0.0027) and CD200 MFI (9,883 [3,514-13,434]; P < 0.0001) were higher in HCL than in HCLv, while CD81 MFI (-1,858 [-2,604 to -1,365]; P < 0.0001) was lower in HCL than in HCLv. CD79b MFI HCL median was more than double that of HCLv, but the observed difference (1,571 [-739 to 4,417]) was consistent with the null hypothesis of no difference (P = 0.13).

conclusionsCD200, CD43, and CD81 are likely differentially expressed between HCL and HCLv, reflecting their differing disease biology. Inclusion of these markers in FCM is potentially informative. © 2019 International Clinical Cytometry Society.

Indexed as

AdultAgedAged, 80 and overAntigens, CDFemaleFlow CytometryGenetic VariationHumansImmunophenotypingLeukemia, Hairy CellLeukosialinMaleMiddle AgedTetraspanin 28Antigens, CDantigens, CD200CD81 protein, humanLeukosialinSPN protein, humanTetraspanin 28B-cell lymphomaB-cell lymphoproliferative disorderCD200CD43CD79bCD81flow cytometryhairy cell leukemiahairy cell leukemia variantimmunophenotypesplenic lymphoma

Identifiers

PMID31077558
PMCPMC8191384
OpenAlexW2944785253

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.